The patients who may have a little toxicity are those who have had locally advanced disease, and we must treat a much bigger area. Miller: So, less trouble with the acute skin toxicity? I think a lot ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

CNW/ - The 2025 Lung Ambition Awards – a Canadian-based lung cancer research award program – is now open for submissions. For ...

Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

He explained that for about eight years in the 80s, he sold mammography equipment, so when he noticed discharge from his ...

SLE is a chronic and complex heterogeneous autoimmune disease in which the immune system dysfunctions and inappropriately ...